2020
DOI: 10.3389/fmicb.2020.583254
|View full text |Cite
|
Sign up to set email alerts
|

Exopolysaccharides From Lactobacillus paracasei Isolated From Kefir as Potential Bioactive Compounds for Microbiota Modulation

Abstract: Bengoa et al. EPS From Lactobacillus paracasei as Microbiota Modulators differences in their structural characteristics. It can be concluded that EPS synthesized by both L. paracasei strains, could be potentially used as bioactive compound that modify the microbiota increasing the production of propionic and butyric acid, two metabolites highly associated with beneficial effects both at the gastrointestinal and extra-intestinal level.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
23
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8
1
1

Relationship

1
9

Authors

Journals

citations
Cited by 31 publications
(25 citation statements)
references
References 73 publications
0
23
0
Order By: Relevance
“…The results observed intervenes with the metabolic factors, property of metabolic syndrome, recovery in fasting insulin and insulin resistance index (HOMA-IR), and a decline in pro-inflammatory cytokines, and systolic and diastolic pressure, proving the modulation of the human gut microbiota through the kefir consumption in patients with metabolic syndrome. Moreover, Bengoa et al [184] evaluated the capacity of the EPS produced by two L. paracasei strains isolated from kefir grains, to be metabolized in vitro by the fecal microbiota. It was observed that both EPS produced CIDCA 8339 (EPS8339) and CIDCA 83124 (EPS83124) that led to changes in fecal microbiota with a significant increase in the production of propionic acid and butyric acid.…”
Section: Future Prospect and Limitationsmentioning
confidence: 99%
“…The results observed intervenes with the metabolic factors, property of metabolic syndrome, recovery in fasting insulin and insulin resistance index (HOMA-IR), and a decline in pro-inflammatory cytokines, and systolic and diastolic pressure, proving the modulation of the human gut microbiota through the kefir consumption in patients with metabolic syndrome. Moreover, Bengoa et al [184] evaluated the capacity of the EPS produced by two L. paracasei strains isolated from kefir grains, to be metabolized in vitro by the fecal microbiota. It was observed that both EPS produced CIDCA 8339 (EPS8339) and CIDCA 83124 (EPS83124) that led to changes in fecal microbiota with a significant increase in the production of propionic acid and butyric acid.…”
Section: Future Prospect and Limitationsmentioning
confidence: 99%
“…Studies analyzing the effects of kefir on the modulation of the intestinal microbiota ( 56 ) and the immune system ( 57 ) have also been carried out. In addition, the microbial non-kefir fraction, known as post-biotics (metabolites produced in the fermentation process of dietary components as well as the endogenous components generated by bacteria-host interactions that influence human health) have been widely studied due to their antagonism against pathogenic bacteria such as Escherichia coli, Salmonella spp.…”
Section: Kefir In Latin Americamentioning
confidence: 99%
“…The colonic fermentation of EPS increases the proportion of the microorganisms belonging to the genera Victivallis, Acidaminococcus, and Comamonas, as well as a substantial decrease in the proportion of enterobacteria. EPS produced by L. paracasei in milk can be considered bioactive compounds because they alter the intestinal microbiome (metabolized in vitro by faecal microbiota producing SCFAs) by enhancing the development of propionic and/or butyric acid, two metabolites that have been linked to a variety of health benefits [127].…”
Section: Kombuchamentioning
confidence: 99%